MX2018014087A - Composicion de marcaje palpable. - Google Patents

Composicion de marcaje palpable.

Info

Publication number
MX2018014087A
MX2018014087A MX2018014087A MX2018014087A MX2018014087A MX 2018014087 A MX2018014087 A MX 2018014087A MX 2018014087 A MX2018014087 A MX 2018014087A MX 2018014087 A MX2018014087 A MX 2018014087A MX 2018014087 A MX2018014087 A MX 2018014087A
Authority
MX
Mexico
Prior art keywords
composition
administration
human
animal body
liquid before
Prior art date
Application number
MX2018014087A
Other languages
English (en)
Inventor
Lars Andresen Thomas
Irming Jølck Rasmus
Maria Bruun Linda
Original Assignee
Univ Denmark Tech Dtu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Denmark Tech Dtu filed Critical Univ Denmark Tech Dtu
Publication of MX2018014087A publication Critical patent/MX2018014087A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0491Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0013Luminescence
    • A61K49/0017Fluorescence in vivo
    • A61K49/005Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0052Small organic molecules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0013Luminescence
    • A61K49/0017Fluorescence in vivo
    • A61K49/005Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0054Macromolecular compounds, i.e. oligomers, polymers, dendrimers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0063Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0073Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form semi-solid, gel, hydrogel, ointment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/22Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A61K49/222Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/226Solutes, emulsions, suspensions, dispersions, semi-solid forms, e.g. hydrogels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1213Semi-solid forms, gels, hydrogels, ointments, fats and waxes that are solid at room temperature
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Optics & Photonics (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Acoustics & Sound (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La presente invención se refiere a una composición de marcaje palpable que comprende carbohidratos no solubles en agua, en donde al menos el 50% de los carbohidratos no solubles en agua son carbohidratos seleccionados de derivados de lactosa, maltosa, trehalosa, rafinosa, glucosamina, galactosamina, lactosamina o derivados de disacáridos con al menos dos unidades de sacáridos de piranosa, trisacáridos, tetrasacáridos o mezclas de los mismos, y en donde la composición es un líquido antes de la administración en el cuerpo humano o animal y aumenta la viscosidad en más de 50,000 centipoises (cP) después de la administración, para usarse para identificar y / o localizar un tumor no palpable. En una modalidad, la composición es un líquido antes de la administración en el cuerpo humano o animal que aumenta su viscosidad en más de 500,000 centipoises (cP) después de la administración en el cuerpo humano o animal. En otra modalidad, la composición es un líquido antes de la administración y tiene la capacidad de transformarse en un sólido cristalino o amorfo después de la administración.
MX2018014087A 2016-05-20 2017-05-19 Composicion de marcaje palpable. MX2018014087A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE1650695 2016-05-20
PCT/EP2017/062181 WO2017198858A1 (en) 2016-05-20 2017-05-19 Palpable marker composition

Publications (1)

Publication Number Publication Date
MX2018014087A true MX2018014087A (es) 2019-06-10

Family

ID=59070598

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018014087A MX2018014087A (es) 2016-05-20 2017-05-19 Composicion de marcaje palpable.

Country Status (13)

Country Link
US (1) US11058780B2 (es)
EP (1) EP3458029A1 (es)
JP (1) JP7086863B2 (es)
KR (1) KR102358040B1 (es)
CN (1) CN109475491B (es)
AU (1) AU2017266410B2 (es)
BR (1) BR112018073493A2 (es)
CA (1) CA3023928A1 (es)
IL (1) IL263071B (es)
MX (1) MX2018014087A (es)
SG (1) SG11201809729XA (es)
WO (1) WO2017198858A1 (es)
ZA (1) ZA201808532B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018168282A1 (ja) 2017-03-15 2018-09-20 株式会社村田製作所 回路モジュール、ネットワークモジュール、及び車載電子機器
WO2019243419A1 (en) * 2018-06-19 2019-12-26 Danmarks Tekniske Universitet Brachygel for treatment of cancer and/or for guidance of surgery
US20210275692A1 (en) * 2018-06-19 2021-09-09 Danmarks Tekniske Universitet Solution comprising fluorescent dye as fiducial marker
US20220339285A1 (en) * 2019-06-12 2022-10-27 Technical University Of Denmark Dissacharide formulations for controlled drug release

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3733397A (en) 1966-12-02 1973-05-15 Pharmacia Ab Method for the x-ray visualization of body cavities and a preparation for carrying out the method
SE344166B (es) 1966-12-13 1972-04-04 Pharmacia Ab
SE315974B (es) 1967-12-28 1969-10-13 Pharmacia Ab
US3804892A (en) 1967-12-28 1974-04-16 Pharmacia Ab Novel 3,5-substituted 2,4,6-triiodobenzoic acids and salts thereof
US3763227A (en) 1967-12-28 1973-10-02 Pharmacia Ab Novel 3,5-substituted 2,4,6-triiodobenzoic acids and salts thereof
DE2628517C2 (de) 1976-06-23 1985-02-21 Schering AG, 1000 Berlin und 4709 Bergkamen Dicarbonsäure-bis(3,5-dicarbamoyl-2,4,6-trijodanilid)-Verbindungen, Verfahren zu ihrer Herstellung und Röntgenkontrastmittel
US4406878A (en) 1978-08-02 1983-09-27 Eastman Kodak Company Iodinated contrast agent for radiography
IT1207226B (it) 1979-08-09 1989-05-17 Bracco Ind Chimica Spa Derivati dell'acido 2,4,6-triiodo-isoftalico, metodo per la loro preparazione e mezzi di contrasto che li contengono.
DE3038853A1 (de) 1980-10-10 1982-05-27 Schering Ag, 1000 Berlin Und 4619 Bergkamen Neue n-hydroxy-alkylierte dicarbonsaeure-bis-(3,5-dicarbamoyl-2,4,6-trijodanilide), deren herstellung und diese enthaltende roentgenkonstrastmittel (ii)
US4439356A (en) 1981-03-03 1984-03-27 Syva Company Unsymmetrical fluorescein derivatives
LU88639I2 (fr) 1982-11-08 1996-02-01 Nycomed Imaging S A Agents de contraste pour rayons x
US5198136A (en) 1986-12-23 1993-03-30 Daikin Industries Ltd. Iodine-containing compound, preparation thereof and block copolymer comprising the same
US5066580A (en) 1988-08-31 1991-11-19 Becton Dickinson And Company Xanthene dyes that emit to the red of fluorescein
IT1245853B (it) 1990-11-16 1994-10-25 Bracco Spa 1,3-bis(3-(mono o poliidrossi)acilamino-5-(mono o poliidrossi-alchil) aminocarbonil-2,4,6-triiodo-benzoil-amino)-idrossi- o idrossi-alchil- propani, loro metodo di preparazione e mezzi di contrasto roentgenografici che li contengono
US5750409A (en) 1991-11-18 1998-05-12 Boehringer Mannheim Gmbh Pentacyclic compounds and their use as absorption or fluorescent dyes
WO1993010758A1 (en) * 1991-12-05 1993-06-10 Pitman-Moore, Inc. A carbohydrate glass matrix for the sustained release of a therapeutic agent
GB9303992D0 (en) 1993-02-26 1993-04-14 Nycomed Imaging As Contrast agents
BRPI9609033B8 (pt) 1995-06-07 2017-04-04 Durect Corp composição e emulsão para a liberação controlada de uma substância.
US6413536B1 (en) 1995-06-07 2002-07-02 Southern Biosystems, Inc. High viscosity liquid controlled delivery system and medical or surgical device
AU6114396A (en) 1995-06-16 1997-01-15 Biophysica Foundation Formyl derivatives as nonionic contrast media
US6008379A (en) 1997-10-01 1999-12-28 The Perkin-Elmer Corporation Aromatic-substituted xanthene dyes
US6270464B1 (en) 1998-06-22 2001-08-07 Artemis Medical, Inc. Biopsy localization method and device
US6072069A (en) 1998-11-04 2000-06-06 Biophysica, Inc. Biodegradable nonionic contrast media
BR9906240A (pt) 1999-06-28 2002-07-23 Temis Lostalo S A Lab Composicoes injetáveis de carvão , em suspensão aquosa estável, método para prepará-las e método de marcacão pré-cirurgica na pesquisa de patologias mamárias nao palpáveis aplicando as referidas composições, uso do carvão ativado de granulometria seletiva para a preparacão das referidas composições
EP1186305A1 (en) 2000-09-07 2002-03-13 Schering Aktiengesellschaft New brominated compounds as contrast media for X-ray mammography
US7371877B2 (en) 2002-03-27 2008-05-13 Fujifilm Corporation Glycerol ester derivative
US20050255045A1 (en) 2004-05-13 2005-11-17 Woltering Eugene A Surgical marking composition and method
JP2011506286A (ja) 2007-12-05 2011-03-03 ジーイー・ヘルスケア・アクスイェ・セルスカプ 造影剤
US20090217932A1 (en) 2008-03-03 2009-09-03 Ethicon Endo-Surgery, Inc. Intraluminal tissue markers
WO2013076305A1 (en) * 2011-11-25 2013-05-30 Danmarks Tekniske Universitet Formulation of solid nano-sized particles in a gel-forming system
US10561746B2 (en) 2013-05-24 2020-02-18 Danmarks Tekniske Universitet Gel formulations for guiding radiotherapy
WO2016079332A1 (en) 2014-11-21 2016-05-26 Technical University Of Denmark Gel formulations for improving immunotherapy
WO2016079331A1 (en) 2014-11-21 2016-05-26 Technical University Of Denmark Gel formulations for enhancing the effect of radiotherapy
EP3220887A1 (en) 2014-11-21 2017-09-27 Technical University of Denmark Gel formulations for local drug release

Also Published As

Publication number Publication date
KR102358040B1 (ko) 2022-01-28
WO2017198858A1 (en) 2017-11-23
CA3023928A1 (en) 2017-11-23
KR20190026662A (ko) 2019-03-13
JP2019519522A (ja) 2019-07-11
IL263071B (en) 2021-12-01
AU2017266410A1 (en) 2018-11-22
SG11201809729XA (en) 2018-12-28
BR112018073493A2 (pt) 2019-03-26
US20190275174A1 (en) 2019-09-12
JP7086863B2 (ja) 2022-06-20
CN109475491B (zh) 2022-06-24
US11058780B2 (en) 2021-07-13
EP3458029A1 (en) 2019-03-27
IL263071A (en) 2018-12-31
AU2017266410B2 (en) 2022-07-14
ZA201808532B (en) 2020-02-26
CN109475491A (zh) 2019-03-15

Similar Documents

Publication Publication Date Title
MX2018014087A (es) Composicion de marcaje palpable.
MX2020011166A (es) Agentes crioprotectores para formulaciones en forma de particulas.
IL279036A (en) Pharmaceutical combination, the composition and preparation of a combination containing an activator of glucokinase and an inhibitor of SGLT-2, preparation methods and their uses
WO2015023976A3 (en) Selective grp94 inhibitors and uses thereof
MX2017007178A (es) Formulaciones liquidas estables de virus de vacuna.
PH12018500499A1 (en) A composition and/or combination for aquaculture
BR112018070140A2 (pt) sistema de distribuição
WO2017100700A3 (en) Peptides for renal therapy
MX2015009552A (es) Composiciones que incluyen agentes para conferir caracter hidrofobico y estabilizantes y metodos para elaborar y usar los mismos.
CL2016000684A1 (es) Coformulaciones de bifentrina con agentes de protección de cultivos encapsulados para uso con fertilizantes líquidos.
MX2018000894A (es) Composicion de fragancia a base de agua, dispositivo de suministro de fragancia, y metodo para proporcionar un perfume de larga duracion.
BR112016007133A2 (pt) coformulações co de bifentrina com agentes de proteção de colheita de alto ponto de fusão para uso com fertilizantes líquidos
MX2019003520A (es) Mezclas y formulacions que comprenden una sal de alquil amonio de acido etilendiaminotetraacetico (edta).
BR112015017246A8 (pt) composição farmacêutica aquosa, seu uso e seringa
WO2016004513A8 (en) Anti-bacterial pyruvate kinase modulator compounds, compositions, uses and methods
MX2017000041A (es) Formulaciones de liberacion inmediata disuasivas de abuso que comprenden polisacaridos no celulosicos.
PH12017500098A1 (en) Suspension compositions of cyclosporin a for subconjunctival and periocular injection
EP4249060A3 (en) Liquid pharmaceutical composition of adalimumab
AU2015297023B2 (en) Anti-adherent composition
BR112018002520A2 (pt) Agonistas de tlr4 e composições dos mesmos e seuuso no tratamento de câncer
WO2016044839A3 (en) Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
TN2017000011A1 (en) Aqueous formulation comprising paracetamol and ibuprofen.
WO2015066302A3 (en) Compositions, methods of use, and methods of treatment
WO2016036966A8 (en) Hydrazinyl lipidoids and uses thereof
BR112017015452A2 (pt) formulação farmacêutica